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A B S T R A C T   
Neurofilament light chain (NfL) is a protein that is selectively expressed in neurons. Increased levels of NfL 
measured in either cerebrospinal fluid or blood is thought to be a biomarker of neuronal damage in neurode-
generative diseases. However, there have been limited investigations relating NfL to the concurrent measures of 
white matter (WM) decline that it should reflect. White matter damage is a common feature of Alzheimer's 
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disease. We hypothesized that serum levels of NfL would associate with WM lesion volume and diffusion tensor 
imaging (DTI) metrics cross-sectionally in 117 autosomal dominant mutation carriers (MC) compared to 84 non- 
carrier (NC) familial controls as well as in a subset (N = 41) of MC with longitudinal NfL and MRI data. 
In MC, elevated cross-sectional NfL was positively associated with WM hyperintensity lesion volume, mean 
diffusivity, radial diffusivity, and axial diffusivity and negatively with fractional anisotropy. Greater change in 
NfL levels in MC was associated with larger changes in fractional anisotropy, mean diffusivity, and radial dif-
fusivity, all indicative of reduced WM integrity. There were no relationships with NfL in NC. Our results de-
monstrate that blood-based NfL levels reflect WM integrity and supports the view that blood levels of NfL are 
predictive of WM damage in the brain. This is a critical result in improving the interpretability of NfL as a marker 
of brain integrity, and for validating this emerging biomarker for future use in clinical and research settings 
across multiple neurodegenerative diseases.   
1. Introduction 
Neurodegenerative disease biomarkers have important roles in de-
fining disease presence and severity, predicting progression, and mon-
itoring disease-modifying therapies. For clinical and research settings 
such in vivo measures include magnetic resonance imaging (MRI), po-
sitron emission tomography (PET), cerebrospinal fluid (CSF) assays, 
and blood-based tests. Blood-based biomarkers (Lewczuk et al., 2018;  
Zetterberg and Blennow, 2018) have the advantages of minimal inva-
siveness, subject acceptability, low cost, as well as accessibility in di-
verse clinical settings, including lesser developed countries. 
Neurofilaments are a component of the cytoskeleton in the neuronal 
axons and are critical for the radial growth and stability of axons (Barry 
et al., 2012; Rao et al., 2003). Any pathological process that leads to 
axonal damage or neuronal death should release neurofilament proteins 
into the surrounding extracellular fluid. Thus, elevations in neurofila-
ment protein biofluid concentrations are not specific to one disease but 
are a general indicator of axonal damage. Neurofilaments have one of 
three basic structures with light, medium, or heavy molecular weights. 
The majority of work in neurodegenerative conditions has focused on 
the light subunit (NfL). 
CSF and blood-based NfL has been evaluated as a potential fluid 
biomarker in a wide range of neurodegenerative disorders (see Bridel 
et al., 2019; Gordon, 2020; Khalil et al., 2018) including frontotemporal 
dementia (FTD) (Meeter et al., 2016; Rohrer et al., 2016; Skillbäck 
et al., 2014), progressive supranuclear palsy (PSP) (Hansson et al., 
2017; Holmberg et al., 1998), amyotrophic lateral sclerosis (ALS) 
(Gaiottino et al., 2013; Lu et al., 2015), Parkinson's disease (PD) 
(Hansson et al., 2017), multiple sclerosis (MS) (Chitnis et al., 2018;  
Disanto et al., 2017; Kuhle et al., 2019), vascular dementia (VAD) (De 
Marchis et al., 2018; Skillbäck et al., 2014), dementia with Lewy bodies 
(DLB) as well as sporadic and autosomal dominant Alzheimer's disease 
(AD) (Gaiottino et al., 2013; Mattsson et al., 2019; Preische et al., 2019;  
Weston et al., 2017, 2019). 
Despite the growing usage of NfL as a biomarker, only a modest 
number of studies have related NfL levels to the markers of white 
matter (WM) health to which it should be intimately related and me-
chanistically linked. Results from MS populations have shown that in-
creased levels of NfL in the CSF or blood were related to greater WM 
hyperintensity (WMH) volumes and gadolinium enhancing lesions 
(Chitnis et al., 2018; Dalla Costa et al., 2019; Disanto et al., 2017; Kuhle 
et al., 2019). A similar pattern was found in patients with ischemic 
stroke (Tiedt et al., 2018) and cerebral autosomal dominant arterio-
pathy with subcortical infarcts and leukoencephalopathy (CADASIL) 
(Gravesteijn et al., 2019). Diffusion tensor imaging (DTI) is a particular 
form of diffusion-weighted imaging that characterizes the movement of 
water molecules in the brain and provides a way to examine micro-
structural changes of WM integrity. Prior studies found that higher le-
vels of NfL are related to worse WM health as captured by higher levels 
of mean diffusivity (MD) and lower fractional anisotropy (FA) (Menke 
et al., 2015; Mielke et al., 2019; Moore et al., 2018)although this is not 
always the case (Mielke et al., 2019; Racine et al., 2019). 
Autosomal dominant AD (ADAD) is a form of AD caused by heri-
table mutations in genes that are involved in the production of beta- 
amyloid (Aβ). The young age at onset (30–60 years) of ADAD means 
individuals are largely free of age-related comorbidities (i.e. vascular 
health) that can contribute to WM disease. The relatively predictable 
age of dementia onset in ADAD also means that one can align asymp-
tomatic individuals relative to their estimated disease onset. This makes 
it possible to investigate decades' worth of the disease course from large 
cross-sectional samples. Such studies of ADAD have shown that CSF and 
blood NfL levels are elevated in symptomatic individuals and begin to 
increase 10–20 years before symptom onset (Preische et al., 2019;  
Sánchez-Valle et al., 2018; Weston et al., 2017), consistent with the 
notion that WM damage is an early event in AD. There is an emerging 
recognition that frank WM lesions as well as changes observed with DTI 
are a core feature of ADAD (Araque Caballero et al., 2018; Lee et al., 
2016). As a result, ADAD can serve as a model to test whether elevated 
levels of NfL are related to changes in WM over the course of the dis-
ease. In the current work we test the sensitivity of NfL as a measure of 
white matter decline in neurodegenerative disorders. We hypothesize 
that serum levels of NfL are associated with WM hyperintensity lesion 
volume and diffusion metrics in both cross-sectional and longitudinal 
cohorts with ADAD. 
2. Materials and methods 
2.1. Participants 
Participants were from the Dominantly Inherited Alzheimer 
Network (DIAN) observational study recruited from 14 study sites in 
the USA, UK, Germany, and Australia. DIAN participants are from fa-
milies with known mutations in presenilin 1 (PSEN1), presenilin 2 
(PSEN2), and amyloid precursor protein (APP) genes and have a 50% 
risk of inheriting the mutation from their affected parent at a relatively 
similar, and therefore predicable, age at onset within families. 
Participants who completed genetic, clinical, neuroimaging, and blood 
draw assessments, and whose data passed quality control as part of the 
11th DIAN data release were considered for this study. The sample was 
restricted to those who had at least one serum NfL measurement, one 
DTI scan, and one T2-weighted fluid-attenuated inversion recovery 
(FLAIR) scan within 1 year of serum NfL measurement. The average 
number of days between blood draw for NfL and DTI scan was 
0.92  ±  0.66 (mean  ±  SE) days. This sample included a subset of 
DIAN participants previously described (Preische et al., 2019). 
The final cross-sectional sample consisted of data from 117 muta-
tion carriers (MC; 87 PSEN1, 12 PSEN2, and 18 APP) and 84 familial 
non-carrier (NC) controls. Of the 117 MC with baseline data, 41 had 
two or more visits with serum NfL measurement, DTI scan, and FLAIR 
scan available for longitudinal analyses (one had four visits, four had 
three visits, and 36 had two visits). 
The institutional review board at Washington University in St. Louis 
provided supervisory review and human studies approval. Participants 
or their caregivers provided written informed consent in accordance 
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with their local institutional review board. Participants' relevant 
background characteristics are listed in Table 1. 
2.2. Clinical 
Cognitive and functional status was assessed using the Clinical 
Dementia Rating (CDR). ‘Presymptomatic’ was defined as CDR = 0, and 
‘symptomatic’ as CDR  >  0. For each visit, a participant's estimated 
years from expected symptom onset (EYO) was calculated based upon 
the participant's current age relative to either the family mutation- 
specific expected age at onset of cognitive symptoms or parental age at 
first progressive cognitive decline if onset for the mutation was un-
known. EYO was established identically for both MC and NC family 
members. The presence or absence of an autosomal dominant AD mu-
tation was determined using PCR-based amplification of the appro-
priate exon followed by Sanger sequencing (Bateman et al., 2012). 
Clinical evaluators were blind to the mutation status of participants. 
2.3. Imaging 
DIAN Imaging data was screened for protocol compliance and ar-
tifacts. All sites used a 3 T scanner, which was qualified for use at study 
initiation and was required to pass regular quality control assessments. 
Volumetric T1-weighted images (repetition time = 2300 ms, echo 
time = 2.95 ms, flip angle = 9°, 1.1 × 1.1 × 1.2 mm3 resolution) were 
acquired for all participants and were processed using FreeSurfer 5.3 
(http://surfer.nmr.mgh.harvard.edu/) (Fischl, 2012) and the Desikan 
atlas to produce regional estimates of grey matter for use in PET pro-
cessing. 
To characterize diffusion, whole brain DTI data were acquired using 
T2*-echo planar imaging with one reference volume (b0, 
b = 1000 mm2) and 64 diffusion directions (repetition time = 6000/ 
7800/11000 ms, echo time = 87/85 ms, flip angle = 90°, b- 
value = 1000/s mm2 2.5 mm isotropic voxels). Only DTI data collected 
on a Siemens scanner was included in the current study. 
2.4. DTI preprocessing 
Preprocessing included correction for motion and eddy-current 
distortions followed by skull stripping with FMRIB software library 
(FSL) 5.0.9. Rigorous motion inspection was applied after eddy-current 
correction. As described above, participants' data underwent rigorous 
inspection for artifacts, including determination of motion, which was 
defined as those who moved > 3.5 mm in more than 10% of the dif-
fusion directions. Thirty-five individuals were excluded from the cur-
rent study due to motion artifacts. 
The diffusion tensor model was fit using dtifit within the FMRIB's 
Diffusion Toolbox included in FSL. Fractional anisotropy (FA) measures 
how much water movement is restricted to one primary direction. FA 
ranges from zero to one, with zero being complete isotropic diffusion 
and one being anisotropic diffusion. Axial diffusivity (DA) and radial 
diffusivity (DR) respectively reflect the movement of water parallel and 
perpendicular to (axis of) the fiber bundle. Mean diffusivity (MD) re-
flects the total amount of diffusion present in all directions. Generally, 
higher FA and lower MD is thought to represent healthier WM integrity. 
FA images from all subjects were nonlinearly aligned to the FMRIB58 
atlas, which is a diffusion specific template in MNI space, and averaged 
to create a mean FA image. A skeletonized atlas was generated from this 
mean image using a threshold of 0.2, which excluded any voxels not 
overlapping in at least 80% of participants. Each diffusion metric (FA, 
DA, DR, and MD) was smoothed with a 2-mm kernel and projected onto 
the skeletonized atlas using the nonlinear registration. Voxel-wise 
analyses were performed on the skeletonized maps using tract based 
spatial statistics (TBSS) in FSL (Smith et al., 2006). 
2.5. DTI regions of interest creation 
Well-studied, anatomically derived tracts provide an alternative 
approach to voxel-wise analyses. For this approach, all DTI metrics 
were also analyzed using previously defined regions of interest (ROIs) 
(Strain et al., 2018) from a group of younger adults from a separate 
cohort (Van Essen et al., 2013). Briefly, deterministic tractography was 
performed with the MedINRIA software in native space, and each 
participant's tracts were then transformed to MNI space. Tracts were 
combined across individuals and limited to only those voxels present in 
a majority of individuals. This resulted in the creation of 20 tracts in-
cluding cingulum (left and right), superior and inferior longitudinal 
fasciculus (left and right), corticospinal (left and right), frontal aslant 
tract (left and right), perforant pathway (left and right), uncinate fas-
ciculus (left and right), fronto-occipital fasciculus (left and right), for-
ceps major, forceps minor, anterior corpus callosum, and posterior 
corpus callosum. This atlas includes several WM tracks that are com-
monly evaluated for DTI analyses and was generated from ROI's de-
scribed in a prior study (Wakana et al., 2007). Similar white matter 
tracks are described in more common atlases like the JHU atlas (Oishi 
et al., 2011). 
These WM ROIs were overlaid to the TBSS derived skeletonized 
atlas and the averaged WM metrics (FA, MD, DA, and DR) were cal-
culated in each ROI. Laterality differences were not expected so the left 
and right side were averaged together, as applicable, resulting in a total 
of 12 final ROIs, to decrease the number of comparisons. A relationship 
between NfL and DTI in this population was expected but the spatial 
topography was unknown. Therefore, we did not limit our analyses to 
any particular WM track but instead assessed several WM tracks that 
covered different areas of the brain to isolate a spatial relationship 
between DTI and NfL. 
MD, DA, and DR values were re-scaled by a factor of 1000 before 
being entered into our analyses in order to generate more interpretable 
regression coefficients. 
2.6. WM hyperintensities 
WMH were quantified on FLAIR scans (repetition time = 9000 ms, 
echo time = 90 ms, TI = 2500 ms, flip angle = 150°, 
0.9 × 0.9 × 5.0 mm3 resolution) using maps generated with the open- 
source lesion segmentation tool for SPM that includes a lesion growth 
algorithm (Schmidt et al., 2012). This algorithm identifies voxels likely 
to be WMH. For the current analyses, we used the global volume of 
identified WMH. WMH volumes were not normally distributed, thus a 
log-transformation was applied. 
Table 1 
Baseline sample characteristics.      
Characteristic Non-carrier  
(N = 84) 
Mutation-carrier  
(N = 117) 
p-Value  
Age (yrs), mean (SD) 40.5 (10.7) 38.6 (10.8) .230 
Sex, female (%) 58.3 50.8 .293 
Years of Education, mean 
(SD) 
14.5 (3.2) 14.1 (3.2) .492 
Body Mass Index, mean (SD) 28.8 (6.0) 30.2 (24.2) .601 
aHypertension, % 16.7 6.8 .080 
aDiabetes, % 2.4 0.0 .230 
Serum NfL (pg/mL), mean 
(SD) 
23.7 (12.5) 33.4 (23.1) .001 
EYO (yrs), mean (SD) – -8.5 (11.0) – 
MMSE, mean (SD) 29.2 (1.2) 27.2 (4.1)  < .001 
Clinical Dementia Rating, 0, 
0.5, ≥ 1, n (%) 
81 (96.4), 3 
(3.6), 0 (0) 
76 (65.0), 32 
(27.4), 9 (7.6)  
< .001 
NfL = Neurofilament light chain; EYO = estimated years from expected 
symptom onset; MMSE = Mini-Mental State Examination. 
a Percent of individuals currently receiving active management and/or 
medication for disease.  
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2.7. Aβ-amyloid PET 
Aβ-amyloid (Aβ) PET imaging was performed after a bolus injection 
of [11C] Pittsburgh Compound B (PiB). Acquisition consisted of a 70- 
min scan starting at injection or a 30-min scan beginning 40 min post- 
injection. Data in the 40–70 min post-injection window were converted 
to regional standardized uptake value ratios (SUVRs) relative to the 
cerebellar grey matter using FreeSurfer-derived ROIs, (Su et al., 2013) 
and were partial volume corrected using a regional spread function 
technique (Rousset et al., 1998; Su et al., 2015). A global measure of 
mean cortical uptake of Aβ burden was derived from cortical regions 
previously shown to have elevated signal in AD (Su et al., 2013). Global 
Aβ positivity was defined as a mean cortical SUVR ≥1.42 (Mishra et al., 
2018; Su et al., 2019; Sutphen et al., 2015; Vlassenko et al., 2016). 
2.8. Serum NfL measurements 
All available DIAN serum samples through the 11th annual data 
release were shipped to the University of Tübingen for analysis. These 
processed data were originally published by Preische and colleagues, 
and a subset was used in the current study. As previously described 
(Preische et al., 2019), fluids were collected in the morning under 
fasting conditions. After blood collection, the tubes were left at room 
temperature for 30 min to allow clotting, and then centrifuged at 
2000 ×g for 15 min. Serum was placed into a single transfer tube 
(#60.541, Sarstedt AG&CO.KG, Nümbrecht, Germany) and im-
mediately frozen on dry ice. NfL measurements were performed using a 
highly sensitive Single Molecule Array (SIMOA) assay using the capture 
monoclonal antibody (mAB) 47:3 and the biotinylated detector anti-
body mAB 2:1 (Uman Diagnostics, Umeå, Sweden). The samples were 
measured in duplicate on a Simoa HD-1 platform (Quanterix) using a 2- 
step neat assay. All samples were measured blinded. As NfL levels were 
non-normally distributed, we applied a log-transformation to this 
measure. 
2.9. Statistics 
2.9.1. Participant characteristics 
To compare background characteristics between mutation MC and 
NC, we performed t-tests and chi-square tests, as appropriate. 
2.9.2. White matter hyperintensities within MC 
As done in prior analyses examining NfL and WM (Chitnis et al., 
2018; Dalla Costa et al., 2019; Gravesteijn et al., 2019; Kuhle et al., 
2019), we examined WMH volumes. All linear mixed effect (LME) 
models were constructed and evaluated using the lme4 and lmerTest 
packages in the R statistical environment. Log transformed WMH vo-
lume was entered as the dependent variable; age, sex, and NfL as fixed 
effects; a separate term for family was included as a random intercept. 
This family term represents the specific family a participant comes 
from. NfL was the predictor of interest. Analyses were performed only 
in MC since, due to their young age, NC are unlikely to have any WMH; 
whereas WMH have been shown to be a common feature in ADAD (Lee 
et al., 2016). We wanted to determine if the relationship between WMH 
and NfL levels were simply driven by WM microstructural changes as 
measured by DTI. Therefore, we repeated our original analysis after 
including a global MD metric as a covariate. 
2.9.3. Voxel-wise analyses of DTI 
To examine whether the associations between baseline WM metrics 
of interest and NfL levels varied by mutation status at the voxel level, 
we implemented linear regression models with skeletonized maps of 
either MD, FA, DA, or DR as the dependent variable and age at visit, sex, 
NfL, mutation status, and a NfL x mutation status interaction as pre-
dictor terms. The initial focus was on the interaction between NfL and 
mutation status. Statistical modeling was performed with the 
Randomise toolbox in FSL (Winkler et al., 2014), a nonparametric 
statistical approach using permutation testing implemented with 5000 
permutations. Significant clusters were identified using threshold-free 
cluster enhancement (TFCE) with a family-wise error corrected sig-
nificance level of p = .05 (Smith and Nichols, 2009). 
Prior work indicates that NfL levels are most informative within MC 
(Preische et al., 2019), suggesting a priori that the interaction term will 
be highly significant. Therefore, as a follow-up analysis, we examined 
the relationship between baseline DTI metrics and NfL within each 
mutation status group to better interpret the interaction and to un-
derstand the relationship between NfL and voxel-wise measures of WM 
within MC and NC, separately. We restricted these analyses to voxels 
that were significant in the interaction analyses described above. We 
ran separate models predicting MD, FA, DA, or DR, as a function of age, 
sex, and NfL. 
2.9.4. ROI analyses of DTI within MC 
An alternate approach to voxel-wise analyses is to use ROIs re-
presenting specific WM tracts. To determine if the relationship between 
WM integrity and NfL is tract specific, we ran a series of LME models in 
each ROI treating age, sex, and NfL as fixed effects and including a 
random intercept for family. Dependent variables were the average WM 
metrics (FA, MD, DA, and DR) from each ROI. As we primarily expected 
the effects to be in MCs (Preische et al., 2019), we restricted the ana-
lyses to this group. 
To correct for multiple comparisons, we implemented a Benjamin- 
Hochberg procedure with a false discovery rate of 5%. Although ana-
lyses were performed for each tract, we focused on the posterior corpus 
callosum, superior longitudinal fasciculus, and corticospinal tracts for 
visualization. These regions were selected as exemplar ROIs as: 1) 
posterior corpus callosum is a region with early WM disruption in 
ADAD and shows the most robust association between NfL and WM 
metrics in our primary analyses; 2) superior longitudinal fasciculus is 
associated with default mode network and executive functioning; and 
3) corticospinal tract, as a control, is relatively spared in AD until very 
late stages. 
Prior work has shown dramatic changes in Aβ PET, structural MRI, 
and WMH (Bateman et al., 2012; Benzinger et al., 2013; Gordon et al., 
2018; Lee et al., 2016; McDade et al., 2018) in the DIAN cohort as the 
disease progresses. In a cohort such as DIAN where there are dramatic 
Fig. 1. Relationship between serum NfL and total white matter hyperintensity 
volume in mutation carriers. Scatterplot showing the relationship between total 
WMH volume and serum NfL in MC (n = 117). The shaded area around the 
linear fit line represents one standard error of the mean from the LME model. 
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changes occurring as the disease progresses there is always a concern 
that statistical relationships can be observed due to the parallel timing 
of biomarker changes rather than true biological relationships. To rule 
out if the association between NfL and DTI was simply driven by other, 
more overt changes in the disease we additionally include global Aβ- 
amyloid, total WMH load and precuneus cortical thickness measures. 
These covariates account for the general disease stage of an individual 
(Aβ-amyloid), overt white matter lesions (WMH), or atrophy that could 
drive Wallerian degeneration (structural MRI). Of the 117 MC included 
in primary analyses, 97 had completed a baseline Aβ PET scan. We 
repeated our original ROI models, with particular focus on the posterior 
corpus callosum, superior longitudinal fasciculus, and corticospinal 
tracts, after adding a global Aβ PET, precuneus cortical thickness, and 
total WMH volume measures as covariates to examine whether they 
altered the relationship between NfL and DTI metrics. We additionally 
provide scatter plots of serum NfL, global Aβ PET, precuneus cortical 
thickness, and total WMH volume to DR in posterior corpus callosum 
and correlation matrix in the supplemental material to better interpret 
the relationship amongst these biomarkers. 
2.9.5. White matter integrity markers and NfL across the course of the 
disease 
ADAD has a long preclinical phase evolving over decades (Bateman 
et al., 2012). To evaluate the relationship of NfL and DTI metrics as a 
function of disease progression, our MC sample was categorized by 
baseline CDR score into presymptomatic (CDR = 0, n = 76) and 
symptomatic (CDR  >  0, n = 28) groups. The presymptomatic group 
was further subdivided by Aβ positivity into early (summary Aβ 
SUVR < 1.42; Aβ-, n = 35) and late (summary Aβ SUVR ≥1.22; Aβ+, 
n = 34) groups. These analyses were restricted to the investigation of 
Fig. 2. Main Effect of serum NfL on DTI metrics in MC. p-Value map (red-yellow) of statistically significant voxel-wise associations of higher NfL and (A) lower 
fractional anisotropy, (B) higher mean diffusivity, (C) higher axial diffusivity, and (D) higher radial diffusivity superimposed on the white matter skeleton (blue), 
within mutation carriers (n = 117). Familywise error-corrected at p = .05. (For interpretation of the references to colour in this figure legend, the reader is referred 
to the web version of this article.) 
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FA and MD DTI metrics as these are the most common DTI metrics 
presented in the literature. We predicted FA and MD values in the 
posterior corpus callosum using LME models that included sex, NfL, 
group (presymptomatic Aβ-, presymptomatic Aβ+, and symptomatic), 
and a NfL x group interaction as the fixed effects and family as the 
random effect. If a significant interaction was present, we compared the 
relationship between NfL and the corresponding diffusion metric be-
tween each group. 
2.9.6. Longitudinal relationship between white matter integrity markers and 
NfL 
Longitudinal data were analyzed using LME models as these models 
can account for covariance introduced by serial measurements within 
the model and are more ideally suited for dealing with variability in 
timing or an unbalanced number of data points. The rate of change in 
NfL (ΔNfL) for each individual was modeled using an LME with fixed 
effects of time from baseline in years, and a random intercept for fa-
mily, as well as random slope and intercept terms for each participant. 
The ΔNfL for each individual was extracted from the model estimates 
for subsequent analyses. The ΔNfL was then used for a second LME 
model where the dependent term for each model was a WM measure of 
interest (MD, FA, DA, and DR DTI measures in posterior corpus cal-
losum ROI and WMH volume) with fixed effect terms for baseline age, 
sex, time from baseline, extracted ΔNfL, and a time from baseline x 
ΔNfL interaction. Models contained random slope and intercept terms 
for participants and random intercepts for family. The primary term of 
interest was the interaction between the ΔNfL and the time from 
baseline term. Models were fitted using lme4 in R. For plotting pur-
poses, LMEs were also used to generate individual rates of change for 
WM integrity markers (ROI MD, FA, DA, and DR measures and WMH 
volume). 
3. Results 
3.1. Participant characteristics 
Demographics are presented in Table 1. 
3.2. Relationship between NfL and WMH in MCs 
Within the MC cohort there was an association between NfL and 
total WMH volume (B[SE] = 2.54 [0.56], p = 1.44e-05). Fig. 1. When 
evaluating whether the relationship between NfL and WMH remained 
after accounting for a global DTI MD measure (as a proxy for overall 
WM changes measured with DTI) we found the relationship between 
WMH and NfL was reduced to a trend (B[SE] = 1.15 [0.58], p = .05). 
This suggests that at least a proportion of the association between NfL 
and WMH is captured by DTI metrics. 
4. Voxel-wise relationship between NfL and baseline DTI metrics 
There were interactions between NfL and mutation status on all four 
DTI metrics (FA, MD, axial diffusivity [DA], and radial diffusivity [DR]; 
see Supplemental Fig. S1). As there was a significant interaction be-
tween NfL and mutation status, we next looked within each mutation 
status group for a main effect of NfL on DTI metrics. Within MCs, a 
strong association between higher NfL levels and low FA was observed 
throughout the skeletonized atlas (Fig. 2a). Similarly, there was a 
strong association between higher NfL levels and higher MD, DA and 
DR levels across all WM tracts (Fig. 2b–d, respectively). The threshold 
free cluster enhancement (TFCE) method (see Methods) within our 
voxel-wise analyses resulted in an inclusive cluster of much of the WM 
voxels, emphasizing a robust and widespread association between NfL 
and WM metrics. To better understand subtle tract-specific variations, 
we subsequently generated a mask containing all significant voxels 
surviving multiple comparisons correction and applied this mask to our 
voxel-wise uncorrected statistical map (Supplemental Fig. S2). Within 
NCs there was no association between NfL levels and FA, MD, DA, or DR 
across the entire cortex (data not shown). 
4.1. Regional association between NfL and baseline DTI metrics in MC 
As an alternative to voxel-wise analyses we utilized 12 ROIs that 
summarized important white matter tracts. There were significant as-
sociations between higher NfL levels and lower FA levels across all 12 
ROIs examined. There were consistent associations between higher NfL 
and higher MD, DA, and DR levels in all tracts examined, with the 
exception of the corticospinal tract. Regression coefficients and p-values 
from statistical models are presented in Table 2. Representative plots 
are shown depicting the relationship between NfL and FA, MD, DA, and 
DR in the posterior corpus callosum (Fig. 3a, d, g, and j), superior 
longitudinal fasciculus (Fig. 3b, e, h, and k), and corticospinal (Fig. 3c, 
f, i, and l) tracts. For exploratory purposes, to better understand whe-
ther there were unique relationships within specific mutation types (i.e., 
PSEN1, PSEN2, and APP), we evaluated the association between NfL 
and a singular region and DTI metric of RD in the posterior corpus 
callosum within each mutation type. (Supplemental Fig. S3). 
Including Aβ PET, cortical thickness, and WMH as additional cov-
ariates in ROI models for posterior corpus callosum, superior long-
itudinal fasciculus, and corticospinal tracts in a subset of 97 individuals 
Table 2 
Main effect of serum NfL on DTI metrics in MC.           
WM tract Fractional anisotropy Mean diffusivity Axial diffusivity Radial diffusivity 
B (SE) p B (SE) p B (SE) p B (SE) p  
Inferior Longitudinal Fasciculus −0.062 (0.01) 1.41E-06 0.090 (0.02) 1.61E-05 0.065 (0.02) .0077 0.102 (0.02) 1.50E-06 
Superior Longitudinal Fasciculus −0.048 (0.01) .00020 0.091 (0.02) 1.34E-06 0.090 (0.02) 2.71E-05 0.094 (0.02) 4.46E-06 
Frontal Occipital Fasciculus −0.071 (0.01) 1.54E-09 0.108 (0.02) 8.03E-09 0.084 (0.02) 2.32E-05 0.124 (0.02) 6.52E-10 
Perforant Pathway −0.106 (0.02) 5.28E-07 0.150 (0.02) 6.78E-08 0.084 (0.04) .0193 0.162 (0.03) 6.40E-09 
Uncinate Fasciculus −0.047 (0.01) 4.73E-05 0.060 (0.02) .00019 0.037 (0.02) .0398 0.071 (0.02) 3.34E-05 
Cingulum −0.088 (0.02) 7.80E-08 0.133 (0.02) 3.69E-09 0.091 (0.03) .00123 0.153 (0.02) 1.93E-10 
Frontal Aslant −0.060 (0.01) 9.83E-08 0.089 (0.02) 4.51E-05 0.088 (0.03) .00197 0.101 (0.02) 6.29E-06 
Corticospinal −0.027 (0.01) .012 0.032 (0.02) .0689 0.007 (0.03) .785 0.042 (0.02) .00826 
Anterior Corpus Callosum −0.119 (0.02) 3.10E-06 0.284 (0.04) 4.31E-10 0.301 (0.06) 4.52E-07 0.279 (0.04) 7.20E-09 
Posterior Corpus Callosum −0.155 (0.02) 4.26E-10 0.321 (0.04) 1.83E-12 0.276 (0.06) 3.76E-06 0.344 (0.04) 8.09E-12 
Forceps Minor −0.074 (0.01) 1.10E-08 0.099 (0.02) 1.60E-07 0.086 (0.02) .000364 0.114 (0.02) 1.24E-08 
Forceps Major −0.087 (0.01) 4.77E-09 0.122 (0.02) 2.24E-08 0.082 (0.02) .000109 0.146 (0.02) 3.14E-09 
Unstandardized regression coefficient B and adjusted p-values for serum NfL from a series of linear mixed effect models in each ROI, which included random 
intercepts for family, and fixed effects for age, sex, and NfL. Dependent variables were the average WM metrics (FA, MD, DA, and DR) from each ROI. N = 117. 
WM = White matter; NfL = Neurofilament light chain; ROI = region of interest; SE = standard error.  
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Fig. 3. Tract-specific white matter measures are associated with serum NfL in MC. Scatterplots depicting the relationship between serum NfL and DTI metrics from 
FA, MD, DA, and DR within three representative ROIs (PCC, SLF, and CST) in MC (n = 117). The shaded area around each linear fit line represents one SE from LME 
models. FA = fractional anisotropy; MD = mean diffusivity; DA = axial diffusivity; DR = radial diffusivity; PCC = posterior corpus callosum; SLF = superior 
longitudinal fasciculus; CST = corticospinal tract; NfL = neurofilament light chain; DTI = diffusion tensor imaging; ROIs = regions of interest; MC = mutation 
carriers; SE = standard error. 
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with Aβ PET available, the relationship between NfL and DTI metrics 
persisted (p values = 5.78e-04, 4.21e-04, 0.020, 4.68e-04 for FA, MD, 
DA, and DR in posterior corpus callosum, and p's = 0.029, 0.002, 
0.038, 0.003 for FA, MD, DA, and DR in superior longitudinal fasci-
culus). The relationship between FA, MD and DR in corticospinal tract 
and NfL remained significant (p's = 0.028, 0.046, 0.015, respectively) 
and relationship between DA in the corticospinal tract and NfL re-
mained nonsignificant in the revised models with Aβ PET and WMH as 
additional covariates. (Full models in Supplemental Table S6). These 
results suggest that the association between NfL and FA or MD is not 
driven solely by Aβ pathology, thinning grey matter, or WMH load. 
4.2. White matter integrity markers and NfL across the course of the disease 
We stratified MC into Symptomatic individuals and Presymptomatic 
Late (Aβ +), and Early (Aβ-) groups. There was a group x NfL effect on 
MD (F = 4.3, p = .017), DA (F = 4.49, p = .014), and a trend for DR 
(F = 2.52, p = .087), but not for FA (F = 0.89, p = .415) in the 
posterior corpus callosum. 
Between-group comparisons revealed that the relationship between 
NfL and MD in the posterior corpus callosum in the Symptomatic group 
was stronger than that of the Presymptomatic Early group (B 
[SE] = 0.285 [0.10], p = .004), and similar to that of the 
Presymptomatic Late group (B [SE] = 0.169 [0.10], p = .095) 
(Supplemental Fig. S4). Similarly, the relationship between NfL and DA 
or DR in the posterior corpus callosum in the Symptomatic group was 
stronger than that of the Presymptomatic Early group (B [SE] = 0.448 
[0.15], p = .004 and B [SE] = 0.239 [0.11], p = .029, respectively), 
and not different from that of the Presymptomatic Late group on DA (B 
[SE] = 0.288 [0.16], p = .068) or DR (B [SE] = 0.164 [0.14], 
p = .143) (Supplemental Fig. S4c, d). There were no differences be-
tween Presymptomatic Early and Presymptomatic Late groups across 
any of the DTI metrics examined (p's  >  0.278). Along with prior work 
showing NfL changes in the symptomatic period (Preische et al., 2019), 
these results suggest that the relationship between NfL and WM is most 
robust in those with cognitive symptoms but may begin in cognitively 
normal MCs with significant Aβ pathology and continue or even in-
tensify with the onset of cognitive symptoms. 
4.3. Longitudinal relationship between white matter integrity markers and 
NfL 
Rate of change in NfL (ΔNfL) was associated with rate of change in 
FA, MD, and DR in posterior corpus callosum (B[SE] = −0.238 [0.05], 
p = 1.74e-05; B[SE] = 0.0004 [9.0e-05], p = 3.02e-04; and B 
[SE] = 0.0005 [8.64e-05], p = 1.42e-06, respectively), but not with 
rate of change in DA (B[SE] = 0.0002[1.58e-04], p = .287) or rate of 
change in WMH (B[SE] = 1.04[0.65], p = .121) (Figs. 4 and 5a–d) 
consistent with the view that changes in NfL reflect increasing white 
matter changes in this cohort as measured with DTI. 
5. Discussion 
NfL is a promising fluid biomarker to study neurodegeneration 
across multiple neurological diseases. Although NfL is thought to reflect 
damage to large myelinated axons there is a paucity of work system-
atically examining how NfL levels relate to established markers of 
macrostructural and microstructural WM damage. In the current work 
we examined whether levels of serum NfL are a reflection of WM lesion 
volumes and DTI metrics of WM integrity. Across all measures in MC, 
we found that elevated levels of serum NfL were significantly associated 
with increased levels of WM pathology. This indicates that a blood- 
based measure of NfL does indeed track WM damage in the brain. 
Due to its predictable age of dementia onset and low comorbidities, 
ADAD serves as a useful model to understand the evolution of AD pa-
thology (Bateman et al., 2012; Moulder et al., 2013). Prior work es-
tablished increases in WMH volumes (Lee et al., 2016) as well as al-
terations in DTI metrics (Araque Caballero et al., 2018) as core features 
of ADAD. Across multiple neurological conditions, increased NfL levels 
in CSF and blood have been tied to greater WMH volumes (Chitnis 
et al., 2018; Dalla Costa et al., 2019; Gravesteijn et al., 2019; Kuhle 
et al., 2013, 2019). Consistent with this work, we found that in MC, 
higher serum NfL levels at baseline are associated with greater WMH 
lesion volumes. However, when we included a global MD DTI measure 
for microstructural WM integrity as a covariate, the relationship be-
tween NfL and WMH was no longer present. This suggests that at least 
some of the information contained by global WMH volumes is also 
reflected in DTI metrics. For exploratory purposes, a correlation matrix 
depicting the relationship between biomarkers examined is presented in 
supplementary material. In the subset with longitudinal data, there was 
a trend that a greater increase in serum NfL was related to increases in 
WMH volume, but this did not approach significance (B 
[SE] = 1.04[0.65], p = .121). 
WMH represent macrostructural WM insults in the brain. In addi-
tion to such overt damage, microstructural changes in WM can be as-
sayed using DTI. There have been inconsistent results establishing 
whether CSF and blood levels of NfL are sensitive to such micro-
structural changes in WM detectable using DTI (Menke et al., 2015;  
Mielke et al., 2019; Moore et al., 2018; Racine et al., 2019; Tiedt et al., 
2018). When examining baseline DTI data using voxel-wise- and ROI- 
based approaches in MC we found that higher levels of serum NfL were 
negatively associated with FA, and positively associated with MD, RD, 
and DA throughout the entire cortex, although effects were strongest in 
posterior regions (Table 2 and Supplemental Fig. 2). Lower FA and 
higher MD, RD, and DA are indicative of a less constrained flow of 
water molecules and are generally viewed as markers of WM damage. 
This widespread pattern of WM decline is consistent with prior work in 
ADAD (Araque Caballero et al., 2018). The strong observed relationship 
suggests that NfL is a robust marker of active microstructural WM da-
mage beyond overt lesions. 
As the mutations in ADAD lead to such a dramatic disease pheno-
type, there is always a concern that significant relationships between 
biomarkers may be due simply to a common time course rather than 
measures being truly interrelated. Even when including Aβ PET and 
cortical thickness as a markers of general disease progression and WMH 
Fig. 4. Longitudinal relationship between serum NfL and WMH in MC. 
Scatterplot showing the relationship between the estimated annual rate of 
change in total WMH volume and the estimated annual rate of change in NfL in 
MC (n = 41). The shaded area around the linear fit line represents one SE from 
the LME model. NfL = neurofilament light chain; WMH = white matter hy-
perintensity; ROIs = regions of interest; MC = mutation carriers; 
SE = standard error. 
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volume to account for macrostructural WM damage, we still found 
highly significant associations between serum NfL levels and DTI me-
trics. The relationship between NfL and DTI was present not only at 
baseline but was consistent over time. In the subsample of MC with 
longitudinal data, a greater rate of serum NfL change was associated 
with greater WM declines in FA, and increases in MD, and RD. 
Establishing such a longitudinal relationship is critical to be able to use 
CSF and blood-based measures of NfL to monitor disease progression 
and to potentially use NfL as a marker of response to disease inter-
vention in clinical trials for AD as well as other neurodegenerative 
disorders. 
The heritability in the onset of dementia in ADAD families provides 
the unique ability to stage individuals relative to their expected time of 
cognitive decline. Stratifying by CDR and Aβ positivity status, we were 
able to examine the relationship between NfL and WM integrity across 
the course of the disease. In asymptomatic MC without advanced dis-
ease progression (Aβ-), levels of NfL were low and WM, assessed with 
DTI, was healthy. As the disease progressed (Aβ+), levels of NfL in-
creased and WM health declined in individuals who were still classified 
as asymptomatic but Aβ+. Finally, there were even further increases in 
NfL and declines in DTI metrics in symptomatic individuals. The dis-
tribution of the groups overlapped and within the entire group of mu-
tation carriers NfL and DTI measures were tightly coupled. This sug-
gests that continuous levels of the biomarkers add to the assessment of 
the health of the brain over and above Aβ positivity status and staging 
by CDR alone. 
The current work is a critical step towards establishing NfL as a 
marker of neurodegeneration that reflects likely WM damage and de-
cline. Still, there are limitations to the current analyses. ADAD is a 
continually progressive neurodegenerative condition with relatively 
stereotyped phenotypes and rates of progression, and manifests during 
a younger age range, during which, secondary comorbidities are un-
common. These features make ADAD a very useful model of AD pa-
thobiology and a model to test the relationship between NfL and WM 
Fig. 5. Longitudinal relationship between NfL and DTI metrics in PCC. Scatterplot showing the relationship between the estimated annual rate of change in serum 
NfL and the estimated annual rate of change in (A) FA in PCC, (B) MD in PCC, (C) DA in PCC, and (D) DR in PCC in MC (n = 41). The shaded area around each linear 
fit line represents one SE from LME models. FA = fractional anisotropy; MD = mean diffusivity; DA = axial diffusivity; DR = radial diffusivity; PCC = posterior 
corpus callosum; NfL = neurofilament light chain; DTI = diffusion tensor imaging; SE = standard error. 
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damage. However, these features may affect the generalizability of the 
current findings to late onset AD. For example the degree of AD pa-
thology seen in ADAD is higher than that seen in late onset AD (Gordon 
et al., 2019), which may make it easier to detect associations. Stroke 
and ischemia have been shown to increase NfL levels (Moseby-Knappe 
et al., 2018; Pujol-Calderón et al., 2019), but it is unclear how chronic 
comorbidities such as obesity, hypertension, and diabetes influence the 
protein. While such age-related comorbidities are low in ADAD, in 
sporadic AD they may represent stronger influences on both white 
matter and NfL levels than primary AD proteinopathies. Given the 
previous mixed findings examining Nfl and white matter in older adult 
cohorts (Mielke et al., 2019; Moore et al., 2018; Racine et al., 2019), 
there may be a lower utility of NfL in sporadic AD. 
Although longitudinal relationships between NfL and WM are rarely 
examined, our longitudinal sample is modest. CSF and blood-based 
biomarkers reflect properties of the brain and body at the time of col-
lection. Prior work suggested that CSF biomarkers of neuronal injury 
decline at symptomatic stages of AD (Llibre-Guerra et al., 2019;  
Sutphen et al., 2018), which could lead to a mismatch between biofluid 
and imaging markers in later stages of disease. Further work is needed 
to test whether the relationship between imaging and NfL measures 
changes at more advanced stages of neurodegenerative conditions. 
Finally, further examinations relating neuroimaging and biofluid 
measures across multiple neurological disorders are needed. In ADAD 
we showed that neuroimaging and biofluid measure are highly related. 
Although elevated in most neurodegenerative conditions (Bridel et al., 
2019; Gordon, 2020), the degree that NfL becomes abnormal varies 
widely between disorders. In other diseases the strength of the re-
lationship between neuroimaging and biofluid measures may be more 
or less robust. 
Biomarkers provide the ability to measure the health of the central 
nervous system in vivo to aid disease diagnosis and prognosis. Blood- 
based markers are minimally invasive and relatively low cost but few 
have been validated against neuroimaging biomarkers (Lewczuk et al., 
2018). NfL in the blood is highly correlated with measures in the CSF 
and is becoming widely adopted in diagnosing and monitoring multiple 
diseases. Our current work supports the view that blood levels of NfL 
reflect WM damage in the brain at least as measured with neuroima-
ging. This is a critical result in improving the interpretability of NfL as a 
marker of brain integrity, and for validating this novel biomarker for 
future use in clinical and research settings. 
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